The nursing assessment reveals a clear, reproducible relationship between levodopa administration and the patient's motor symptoms. The writhing, twisting movements of the arms and trunk occur approximately
1 hour after the
06:00 and
10:00 doses, which corresponds to the time when plasma levodopa concentration reaches its maximum. This pattern is characteristic of
peak-dose dyskinesia, a choreiform involuntary movement that emerges when dopaminergic stimulation in the striatum is highest. In contrast, the stiffness, slowness, inability to rise from the chair, and freezing of gait observed at
09:40 and
13:45 occur just before the next scheduled dose, when the levodopa effect has declined. This is the classic presentation of
end-of-dose wearing-off.
The timing of symptoms relative to each levodopa dose is the single most important clue for distinguishing peak-dose dyskinesia from wearing-off and from other motor complications. The patient takes carbidopa-levodopa
25/100 mg every
4 hours during the day. With this short interval, the drug level rises quickly after ingestion and falls before the next dose. The dyskinesia appears when the level is high, and the parkinsonian symptoms return when the level is low. This biphasic pattern—hyperkinetic movements at peak and hypokinetic symptoms at trough—is a hallmark of advancing Parkinson disease with long-term levodopa therapy.
Watch out! Tardive dyskinesia is not the correct interpretation. Tardive dyskinesia is caused by chronic exposure to
dopamine receptor antagonists, such as typical antipsychotics or metoclopramide, not by levodopa. Levodopa-induced dyskinesia has a different pathophysiology and a different temporal relationship to drug dosing. The patient has no reported history of antipsychotic use.
Key point! Biphasic dyskinesia, which appears at the beginning and end of a dose when levodopa levels are rising or falling, is a distinct phenomenon from peak-dose dyskinesia. In this patient, the dyskinesia occurs only about
1 hour after the dose, not at the onset and offset of the dose effect. Therefore, the pattern is peak-dose dyskinesia, not biphasic dyskinesia.
The pathophysiology of levodopa-induced dyskinesia involves pulsatile stimulation of dopamine receptors. As Parkinson disease progresses, nigrostriatal dopaminergic neurons degenerate further, and the brain loses its ability to buffer fluctuations in levodopa levels.
The remaining dopamine terminals can no longer store and release dopamine gradually, so each oral dose produces a sharp spike in striatal dopamine, followed by a rapid decline. This non-physiologic, pulsatile receptor stimulation is thought to drive both dyskinesia at peak levels and wearing-off at trough levels.
The distinction between peak-dose dyskinesia and wearing-off has direct implications for treatment.
If the nurse reports the timing pattern accurately, the physician can adjust the levodopa regimen—for example, by reducing the individual dose size to lessen peak-dose dyskinesia, shortening the dosing interval to reduce wearing-off, or adding adjunctive medications such as a COMT inhibitor or dopamine agonist. Without this timing information, the physician cannot determine whether the problem is too much levodopa at peak or too little levodopa at trough.
The assessment of motor fluctuations can be structured by asking the patient or caregiver about the relationship between symptoms and medication timing. A systematic approach includes documenting the time of each dose, the time of onset and offset of dyskinesia, and the time of onset and offset of parkinsonian symptoms. In this case, the nurse's observation over one day provides exactly that information: dyskinesia at
07:15 and
11:15, wearing-off at
09:40 and
13:45.
The following table summarizes the clinical distinction between the key motor complications in levodopa-treated Parkinson disease.
| Motor complication | Timing relative to levodopa dose | Clinical features | Pathophysiology |
|---|
| Peak-dose dyskinesia | 1 to 2 hours after dose, at peak plasma level | Choreiform writhing, twisting movements; may involve limbs, trunk, neck | Pulsatile high striatal dopamine stimulation |
| End-of-dose wearing-off | Just before next dose, at trough plasma level | Return of stiffness, slowness, freezing, difficulty rising; may include nonmotor symptoms | Decline in striatal dopamine below threshold |
| Biphasic dyskinesia | At onset and offset of each dose effect, when levels are rising or falling | Dyskinesia at both start and end of dose benefit; often affects legs with dystonic features | Transitional dopamine levels crossing a narrow therapeutic window |
| Random on–off fluctuations | Unpredictable, not clearly related to dose timing | Sudden shifts between mobility and immobility without warning | Complex receptor and downstream signaling changes; less predictable than simple pharmacokinetic fluctuations |
The reported observations fit the first two rows of the table, not the last two. The dyskinesia is consistently tied to the post-dose peak, and the parkinsonian symptoms are consistently tied to the pre-dose trough. This predictability argues against random on–off fluctuations, which by definition lack a clear relationship to dose timing.
From a nursing process perspective, the priority is to
report the objective, time-stamped motor observations to the physician. The nurse should document the exact time of each dose, the exact time of each dyskinetic episode, and the exact time of each episode of stiffness, slowness, or freezing. This documentation allows the physician to make a rational pharmacologic adjustment. The nurse should also assess for safety concerns related to freezing of gait and dyskinesia, such as fall risk, and implement appropriate precautions while awaiting medication changes.